Personalized medicine for AML?

Blood

Volumn 116, Issue 15, 2010, Pages 2622-2623

  Smith, Franklin O ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CEBPALPHA PROTEIN; CYTARABINE; FLT3 LIGAND; K RAS PROTEIN; NUCLEOPHOSMIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; GENE ACTIVATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOMICS; HUMAN; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 77957959658     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-296418     Document Type: Note

References (6)

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-1542.
2. Bachas C, Schuurhuis GJ, Hollink IHIM. High frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood. 2010;116(15):2752-2758.
3. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: a report of three consecutive phase III trials by the Children's Cancer Group: CCG251, CCG213 and CCG 2891. Leukemia. 2005;19(12):2054-2062.
4. Brown P, Smith FO. Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date. Paediatr Drugs. 2008;10(2):85-92. (Pubitemid 351414756)
5. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661. (Pubitemid 44864541)
6. Wade N. A decade later, genetic map yields few new cures. The New York Times. June 13, 2010; page A1.